PD-L1 level is highly associated with the degree of response and survival benefit.24 The large difference of ORRs observed in patients diagnosed with advanced NSCLC treated with atezolizumab between IMpower110 (38.2% ORR with SP142) and CITYSCAPE (24% ORR with 22C3) may have been the result of different assays being used when selecting patients.55,73 Therefore, any comparison between patients receiving cemiplimab in EMPOWER-Lung 1 and atezolizumab in IMpower110 would have included patients with differing PD-L1 levels. Here, CD274 is linked to non-small cell lung carcinoma.